Table 2.
Cholinergic-based treatments which have demonstrated beneficial effects in pre-clinical HD studies. Strength of evidence criteria was based on proper study design, number of subjects improved, level of improvement, lack of side effects and replication by others
Treatment | Beneficial effect(s) | Animal model | Number of animals studied | Reference(s) | Strength of | Comments |
evidence | ||||||
Donepezil | improves cognitive function | R6/2 transgenic mice | First study: n = 73 (across 4 groups); second study: n = 55 (across 4 groups) | [66] | 8/10 | Appropriate study design, appropriate mouse model, high number of mice used, results replicated in individual studies. |
Galantamine | reduces neurological deficits, striatal lesions and apoptosis | 3-nitropropionic acid rat model | n = 46 (across 5 groups) | [69] | 4/10 | Appropriate study design although some groups with low numbers of mice, animal model used not ideal. |
VU0467154 | improves motor and synaptic function | YAC128 transgenic mice | Motor function: n = 41 (across 4 groups); synaptic function: n = 43 (across 4 groups) | [85] | 6/10 | Appropriate study design, highly valid animal model used. |
Physostigmine | increases hippocampal cell proliferation | Wistar rats | n = 30 (across 5 groups) | [79] | 4/10 | Animal model not HD-specific, relatively low numbers of animals. |
Oxotremorine | increases hippocampal cell proliferation, spatial working memory and reverses deficits in hippocampal neurogenesis | Wistar rats | n = 30 (across 5 groups) | [79] | 5/10 | Multiple beneficial effects but animal model not HD-specific. |
NGF | improves motor and cognitive function; increases cholinergic cell survival, expression of ChAT, VAChT and trkA markers, hippocampal neurogenesis; reduces excitotoxicity and cholinergic cell atrophy | R6/1 mice, YAC128 mice, Sprague-Dawley rats, Wistar rats | R6/1 mice: n = 48 (across 4 groups); YAC128 mice: n = 64 (across 4 groups); SD rats study 1: n = 29 (across 4 groups); SD rats study 2: n = 27 (across 4 groups); SD rats study 3: n = 37 (across 4 groups); SD rats study 4: n = 18 (across 3 groups) | [48, 87, 88, 90–95] | 9/10 | Appropriate study designs, valid animal models used, numerous beneficial effects reported, beneficial effects found by multiple research groups. |
Wistar rats: n = 8 (across 2 groups) |